TRACON Pharmaceuticals Inc
OTC:TCON
TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 19 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The firm's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. The company is headquartered in San Diego, California and currently employs 19 full-time employees. The company went IPO on 2015-01-30. The firm is focused on the development and commercialization of targeted therapeutics for cancer. The firm's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
